SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

NBIS is trending following a multi-billion dollar agreement with Microsoft to provide AI infrastructure, fueling excitement around the company's growth potential in the AI cloud sector. The community is buzzing about the size and impact of the deal, with some suggesting it could lead to significant revenue growth and new all-time highs. Some analysts see the stock as undervalued given the broader context of increased AI infrastructure spending.

Eightco Holdings, Inc. is a publicly traded holding company, which operates in the consumer products and e-commerce markets, focusing on developing and deploying innovative technology, and capital solutions to empower small to medium-sized businesses. It operates through the North America and Europe geographical segments. The company was founded in 1966 and is headquartered in Easton, PA.

Eightco Holdings Inc

Eightco Holdings Inc ($OCTO) experienced extreme volatility, surging thousands of percentage points following news of a significant crypto treasury investment, leading to a frenzy among day traders and short sellers. The community is actively debating whether the massive gains are sustainable, with many pointing to potential dilution and insider selling, while others anticipate a continued squeeze. Speculation is high as traders look for the next stock to replicate $OCTO's meteoric rise, leading to increased attention on other low-float and crypto-related stocks.

QuantumScape Corp. engages in developing next-generation solid-state lithium-metal batteries. The company’s next-generation batteries are designed to enable greater energy density, faster charging, and enhanced safety to support the transition away from legacy energy sources toward a lower-carbon future. The company was founded by Jagdeep Singh, Tim Holme, and Fritz B. Prinz in May 2010 and is headquartered in San Jose, CA.

QuantumScape Corp - Ordinary Shares - Class A

QuantumScape Corp

QuantumScape is trending due to a live demonstration of its solid-state batteries powering a Ducati motorcycle, showcasing faster charging and higher energy density which has sparked optimism about the technology's potential and real-world application. The community is discussing the implications of this milestone, including potential partnerships with major automakers and the possibility of a short squeeze. However, some are cautious, pointing to the long timeline for commercial production and past disappointments.

Galaxy Digital, Inc. engages in digital assets and data center infrastructure, delivering solutions that accelerate progress in finance and artificial intelligence. It operates through the following segments: Digital Assets and Data Centers. The digital assets segment offers institutional access to trading, advisory, asset management, staking, self-custody, and tokenization technology. The Data Centers segment competes with a range of infrastructure providers that are building or repurposing facilities to support the rapidly growing demand for AI and compute-intensive workloads. The company was founded by Michael Novogratz in 2018 and is headquartered in New York, NY.

Galaxy Digital Inc. - Ordinary Shares - Class A

Galaxy Digital ($GLXY) is trending amid a boost from positive data center news related to $NBIS. Community members believe $GLXY is undervalued, given its significant data center infrastructure, with some speculating a new all-time high is coming. Others are closely watching for Q3 results and any updates regarding ERCOT approval.

Planet Labs PBC provides daily data and insights about earth. It offers a web-geo platform with satellite data available and foundational analytics to derive insights to make decisions. The company is founded by William S. Marshall and Robert H. Schingler in 2010 and is headquartered in San Francisco, CA.

Planet Labs PBC - Ordinary Shares - Class A

Planet Labs PBC

Planet Labs is trending due to a proposed $300M private offering of convertible senior notes, announced after a positive earnings call, leading to concerns about dilution and prompting community discussion around the timing and necessity of the offering. While some investors see it as a strategic move for long-term growth and warrant management, others view it as a deceptive practice that takes advantage of retail investors after a strong earnings report. The community is actively debating the implications of the offering, including conversion prices, capped call strikes, and potential impact on share value and future growth prospects.

Dogecoin is a cryptocurrency based on the popular "Doge" Internet meme and features a Shiba Inu on its logo. Dogecoin is a Litecoin fork. Introduced as a "joke currency" on 6 December 2013, Dogecoin quickly developed its own online community and reached a capitalization of US$60 million in January 2014. Compared with other cryptocurrencies, Dogecoin had a fast initial coin production schedule: 100 billion coins were in circulation by mid-2015, with an additional 5.256 billion coins every year thereafter. As of 30 June 2015, the 100 billionth Dogecoin had been mined.   Dogecoin was created by Billy Markus from Portland, Oregon and  Jackson Palmer from Sydney, Australia. Both wanted to create a fun cryptocurrency that will appeal beyond the core Bitcoin audience. Dogecoin is primarily used as a tipping system on Reddit and Twitter where users tip each other for creating or sharing good content. The community is very active in organising fundraising activities for deserving causes.  The developers of Dogecoin haven’t made any major changes to the coin since 2015. This means that Dogecoin could get left behind and is why Shibas are leaving Dogecoin to join more advanced platforms like Ethereum. One of Dogecoin strengths is its relaxed and fun-loving community. However, this is also a weakness because other currencies are way more professional.  To purchase Dogecoin, it involves downloading a crypto wallet, setting up a crypto exchange account and then trading away for your desired crypto currency. Once we have set up an account with a DOGE currency exchange and deposited some funds, you are ready to start trading.

Dogecoin

Dogecoin is trending amid community excitement, with some eyeing the .24 resistance level and speculating on potential ETF approvals. A recent acquisition of 285M DOGE by CleanCore to initiate its Dogecoin treasury strategy has also fueled bullish sentiment. Despite its meme coin origins, discussions around institutional adoption and potential for significant price movement are driving the conversation.

BrokeCoin is a meme-meets-utility cryptocurrency project operating under the ethos of Transparency, Community, and Respect. Formally registered as an LLC in Wyoming, USA, BrokeCoin is building an expansive ecosystem that combines light-hearted spirit of meme culture with real-world crypto utilities—spanning gaming, staking, NFTs, web services, and an e-commerce platform. Brokecoin believes in developing useful and interesting meme-inspired utilities to both service the crypto industry, and generate value for holders.

Brokecoin

Brokecoin is trending as the community rallies around upcoming burns, staking app launch, and new contests, fueling excitement. Chatter revolves around the strong community, often referred to as "chads", and the project's commitment to a long-term vision. The focus remains on community growth, with members highlighting the coin's organic rise and commitment to future utilities.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

Microsoft is trending due to news of Nebius entering a multi-billion dollar commercial agreement for AI infrastructure, sparking community excitement about the potential impact on both companies. Traders are also monitoring Microsoft's position in the AI landscape, especially compared to Nvidia, as Polymarket data indicates a strong belief in Nvidia's dominance by the end of the month. Community members are actively discussing the implications of this AI infrastructure deal.

Sentage Holdings, Inc. engages in the financial services, which offers a comprehensive range of financial services across consumer loan repayment and collection management, loan recommendation, and prepaid payment network services in China. The company was founded on September 16, 2019 and is headquartered in Shanghai, China.

Sentage Holdings Inc - Ordinary Shares - Class A

Sentage Holdings Inc

Sentage Holdings Inc is trending due to speculative interest, drawing comparisons to recent high-flying low floaters like $OCTO and $MGIH. Community chatter suggests anticipation for a potential short squeeze and after-hours momentum. Some traders are also noting the stock's low float and potential for significant price movement, while others caution about its fundamentals.

Casey's General Stores, Inc. engages in the provision of management and operation of convenience stores and gasoline stations. It provides self-service gasoline, a wide selection of grocery items, and an array of freshly prepared food items. The firm offers food, beverages, tobacco products, health and beauty aids, automotive products, and other non-food items. The company was founded by Donald F. Lamberti in 1968 and is headquartered in Ankeny, IA.

Casey`s General Stores, Inc.

Casey's General Stores, Inc.

CASY is trending as investors discuss the potential impact of upcoming earnings on the stock's trajectory, with community members debating whether it will be a bull trap or a sustained rally. The stock's valuation and recent performance are key points of contention, as some question whether it is overvalued, while others highlight its growth potential and dividend increases. Community members are also sharing information regarding recent news, analyst ratings, and historical performance.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/tag/shuttle-pharmaceuticals">Shuttle Pharmaceuticals (NASDAQ: SHPH)</a> is doubling down on its mission to revolutionize cancer treatment with radiation therapy. In just a few short weeks, the company has achieved a series of notable milestones, from a promising Phase 2 trial update to the appointment of veteran biotech executive George Scorsis as Chairman of the Board.With its lead candidate Ropidoxuridine already making waves in glioblastoma trials, Shuttle Pharma is positioning itself at the forefront of oncology innovation. The moves come as Shuttle looks to emulate recent breakthroughs by industry leaders such as <a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/tag/lantheus-holdings/">Lantheus Holdings (NASDAQ: LNTH)</a> and <a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/tag/novartis/">Novartis (NYSE: NVS)</a>, both of which have brought radiopharmaceutical therapies to market using similar underlying science.<h3>George Scorsis Steps In as Chairman</h3>On Wednesday, <a target="_blank" rel="noopener noreferrer nofollow" href="https://shuttlepharma.com/shuttle-pharma-appoints-george-scorsis-chairman-of-the-board-of-directors/">Shuttle Pharma announced</a> George Scorsis as the new Chairman of its Board of Directors. Scorsis brings over 25 years of executive experience, particularly in highly regulated sectors including biotech and cannabis. His resume includes leadership roles at Liberty Health Sciences and Mettrum Health Corp., and he currently chairs both <a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/tag/awakn-life-sciences">Awakn Life Sciences (CSE: AWKN) (OTCQB: AWKNF)</a> and Entourage Health Corp.Commenting on <a target="_blank" rel="noopener noreferrer nofollow" href="https://shuttlepharma.com/shuttle-pharma-appoints-george-scorsis-chairman-of-the-board-of-directors/">his new role</a> at Shuttle, Scorsis stated:<blockquote>I am honored to take on the role of Chairman of Shuttle Pharma. The Company has a unique opportunity to leverage its radiation sensitizers to increase cancer cure rates, prolong patient survival and improve quality of life for patients suffering from glioblastoma. I look forward to providing guidance to support the Company as we look to improve the lives of millions of patients impacted by cancer.</blockquote>Scorsis also previously served as Chairman of <a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/tag/sol-global-investments">SOL Global Investments (CSE: SOL) (OTC: SOLCF)</a>, which further illustrates his deep involvement in pioneering healthcare ventures.His appointment reflects Shuttle’s strategic push to strengthen its leadership team as it enters a pivotal period of clinical and commercial development.<h3>Ropidoxuridine Phase 2 Trial Gains Momentum</h3>The heart of Shuttle Pharma’s pipeline is <a target="_blank" rel="noopener noreferrer nofollow" href="https://shuttlepharma.com/therapeutics/ropidoxuridine/">Ropidoxuridine</a> (IPdR), a novel radiation sensitizer currently in Phase 2 clinical trials for the treatment of glioblastoma. The aggressive brain cancer has limited treatment options and remains incurable. Shuttle’s approach aims to amplify the efficacy of radiation therapy while keeping side effects minimal.As of <a target="_blank" rel="noopener noreferrer nofollow" href="https://shuttlepharma.com/shuttle-pharma-fda-orphan-drug-nears-patient-enrollment-milestone-for-phase-2-clinical-trial/">May 8, 2025</a>, nearly 50% of the trial’s initial enrollment target had been met. Impressively, 84% of patients enrolled had completed all seven cycles of treatment. Trial sites—ranging from Georgetown University Medical Center to the Miami Cancer Institute—reported the drug was well tolerated, with toxicity scores not exceeding 2 on a 1-5 scale.Dr. Anatoly Dritschilo, who recently stepped down as Chairman and Chief Scientific Officer, <a target="_blank" rel="noopener noreferrer nofollow" href="https://shuttlepharma.com/shuttle-pharma-fda-orphan-drug-nears-patient-enrollment-milestone-for-phase-2-clinical-trial/">said</a>, “If approved, we believe that Ropidoxuridine has the potential to redefine the standard approach for how to care for patients with glioblastoma.”Patients are being randomized into two dose cohorts—1,200 mg/day and 960 mg/day—to determine the optimal regimen. Once identified, an additional 14 patients will be enrolled at the best dose to reach statistical significance. The trial aims to complete enrollment later this year, with data readouts expected in 2026.Chris Cooper, Shuttle’s interim CEO, <a target="_blank" rel="noopener noreferrer nofollow" href="https://shuttlepharma.com/shuttle-pharma-provides-corporate-update/">commented</a>:<blockquote>With nearly 50% of patient enrollment achieved in the initial randomized portion and 84% of enrolled patients completing all seven cycles, the trial is advancing steadily at esteemed cancer centers. Ropidoxuridine has been well-tolerated and we have begun analyzing pharmacokinetic and pharmacodynamic samples to optimize dosing and response. Our goal is to complete enrollment later this year, with follow-up and data readouts anticipated in 2026.</blockquote>The U.S. FDA has granted Orphan Drug Designation to Ropidoxuridine, giving Shuttle potential marketing exclusivity if approved. Given that an estimated 800,000 U.S. cancer patients undergo radiation therapy annually—and 400,000 of those for curative purposes—Shuttle’s target market is sizable and growing.Also Read: <a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/featured/5-minute-deep-dive-scorecard-is-shuttle-pharmaceuticals-nasdaq-shph-ready-for-a-massive-breakout/">5-Minute Deep Dive Scorecard: Is Shuttle Pharmaceuticals (NASDAQ: SHPH) Ready for a Massive Breakout?</a><h3>Innovation Extends Beyond the Clinic</h3>On May 15, 2025, Shuttle released a <a target="_blank" rel="noopener noreferrer nofollow" href="https://shuttlepharma.com/shuttle-pharma-provides-corporate-update/">corporate update</a> highlighting the company’s many recent developments. In addition to clinical progress, Shuttle has made strides in the diagnostics space. The company entered a sponsored research agreement with the University of California, San Francisco (UCSF) to develop a PSMA-targeted ligand for theranostic use in prostate cancer.Furthermore, Shuttle filed a <a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/stocks/biotech/shuttle-pharma-targets-prostate-cancer-with-psma-ligand-breakthrough/">provisional patent</a> titled “PSMA-Targeted PARP Inhibitor Conjugates for Precision Cancer Therapy.” The filing was developed with Dr. Alan Kozikowski, a medicinal chemist whose past work helped enable the development of Lantheus’ Pylarify and Novartis’ Pluvicto—two commercially successful radiopharmaceuticals.Shuttle’s recent underwritten <a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/stocks/biotech/shuttle-pharma-closes-5-75-million-offering/">public offering</a> helped solidify its financial footing, with $4.5 million in cash and equivalents reported as of March 31, 2025. That cash will fund both the ongoing clinical trial and preclinical research efforts.<h3>Strengthened Leadership Amid Key Transitions</h3>While Scorsis’ arrival marks a new chapter, Shuttle has also seen notable exits. Dr. Dritschilo resigned from the Board and his role as CSO, while Michael Vander Hoek, the company’s VP of Regulatory, announced his retirement effective June 10.New board members Oleh Nabyt and Joseph Tung join Scorsis in reinforcing Shuttle’s governance and bringing expanded business and legal acumen to the table.<h3>Looking Ahead</h3>Shuttle Pharmaceuticals appears to be building momentum across multiple fronts—clinical, intellectual property, diagnostics, and leadership. With a new Chairman in place, promising mid-trial results, and a strengthened pipeline backed by a scientific pedigree, the company is drawing comparisons to past success stories, such as Lantheus Holdings and Novartis.Investors will watch closely as the Ropidoxuridine trial progresses toward full enrollment and data publication in 2026. If Shuttle can successfully deliver on its ambitions, it could play a major role in transforming radiation therapy for cancer patients worldwide.Read Next: <a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/videos/shuttle-pharma-showcases-cancer-treatment-advancements-at-planet-microcap-vegas-2025/">This Biotech Stock Took The Center Stage at the Planet MicroCap Showcase: VEGAS 2025</a><a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/sign-up/">Our email list eats first! Get exclusive alerts on explosive stock picks like AST SpaceMobile (NASDAQ: ASTS), which shot up +533% after our profile. Get our email signals based on our proprietary 5-indicator system before any of our other platforms by clicking here.</a><a target="_blank" rel="noopener noreferrer nofollow" href="https://www.facebook.com/groups/WealthyVC">Join the Discussion in the WVC Facebook Investor Group</a>Do you have a stock tip or news story suggestion? Please email us at: <a target="_blank" rel="noopener noreferrer nofollow" href="mailto:invest@wealthyvc.com">invest@wealthyvc.com</a>.This report/release/profile is a commercial advertisement and is for general information purposes only. We are engaged in the business of marketing and advertising companies for monetary compensation unless otherwise stated below.Wealthy VC and its employees are not Registered Investment Advisors, Broker-Dealers or a member of any association for other research providers in any jurisdiction whatsoever and we are not qualified to give financial advice. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Wealthy VC encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled through their website, news releases, and corporate filings, or is available from public sources and Wealthy VC makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. Our website and newsletter are for entertainment purposes only. This website is NOT a source of unbiased information. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment.Release of Liability: Through the use of this email and/or website advertisement, by viewing or using it, you agree to hold Wealthy VC, its operators, owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. Wealthy VC-sponsored advertisements do not purport to provide an analysis of any company’s financial position, operations or prospects and this is not to be construed as a recommendation by Wealthy VC or an offer or solicitation to buy or sell any security. WealthyVC and our controlling entity 1000724287 Ontario Ltd have been compensated USD $7,500 per month for six months for investor relations by Shuttle Pharmaceuticals Holdings, Inc.None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provided herein. Instead, Wealthy VC strongly urges you to conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D and all reports published on SEDAR if the company featured is Canadian. Wealthy VC further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s investment may be lost or impaired due to the speculative nature of the companies profiled.The Private Securities Litigation Reform Act of 1995 provides investors with a ‘safe harbor’ in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact and may be “forward-looking statements”. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements in this action may be identified through the use of words such as “projects”, “foresee”, “expects”, “will”, “anticipates”, “estimates”, “believes”, “understands”, or that by statements indicating certain actions “may”, “could”, or “might” occur. Understand there is no guarantee past performance will be indicative of future results. Past Performance is based on the security’s previous day’s closing price and the high of-day price during our promotional coverage.In preparing this publication, Wealthy VC has relied upon information supplied by various public sources and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this email and website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. The advertisements in this email and website are believed to be reliable, however, Wealthy VC and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of material facts from such advertisement. Wealthy VC is not responsible for any claims made by the companies advertised herein, nor is Wealthy VC responsible for any other promotional firm, its program or its structure.<a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/disclaimer/">View Full Disclaimer</a>

Shuttle Pharma Ramps Up Fight Against Glioblastoma With New Leadership, Promising Clinical Trial, and Bold Innovations

Others

George Scorsis takes helm as Chairman as Ropidoxuridine trial nears 50% enrollment and patent advances boost pipeline.

Lantheus to Acquire Evergreen Theragnostics for Upfront Payment of $250 Million to Drive Strategic Evolution into Fully Integrated Radiopharmaceutical Leader

Lantheus to Acquire Evergreen Theragnostics for Upfront Payment of $250 Million to Drive Strategic Evolution into Fully Integrated Radiopharmaceutical Leader Lantheus to Acquire Evergreen...

Peering Into Lantheus Holdings's Recent Short Interest

Cancer Research Sees Major Boost as New Breakthroughs Emerge from Key Oncology Players

Cancer Research Sees Major Boost as New Breakthroughs Emerge from Key Oncology Players Cancer Research Sees Major Boost as New Breakthroughs Emerge from Key Oncology Players PR Newswire VANCOUVER...

XPeng & QuantumScape Are Among Top 11 Mid Cap Stocks That Performed Well Last Week (July 7-July 13): Details

10 mid-cap stocks jumped in last week, including QuantumScape, Lantheus Holdings, Sunrun, Kymera Therapeutics, Apogee Therapeutics, Joby Aviation, Crinetics Pharmaceuticals, Dyne Therapeutics, Summit...

Why Lantheus Holdings Stock Is Skyrocketing Today

Why Lantheus Holdings Stock Is Skyrocketing Today...

Evaluating Lantheus Holdings: Insights From 5 Financial Analysts

Latest Ratings for LNTH
 DateFirmActionFromTo Feb 2022SVB LeerinkMaintainsOutperform Jul 2021SVB LeerinkMaintainsOutperform May 2021Credit SuisseMaintainsNeutral
 View More Analyst Ratings for...

Interesting LNTH Put And Call Options For May 17th

Investors in Lantheus Holdings Inc (LNTH) saw new options begin trading this week, for the May 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the LNTH...

Lantheus Holdings (LNTH, $60.11) Moving Average Convergence Divergence (MACD) Histogram turned positive on April 1, 2024

This is a Bullish indicator signaling LNTH's price could rise from here. Traders may explore going long the stock or buying call options...

Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Year 2023 Financial Results

SEATTLE, March 28, 2024 (GLOBE NEWSWIRE) -- Perspective, Therapeutics, Inc. (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers...

Lantheus Holdings, Inc. engages in the provision of diagnostic imaging and nuclear medicine products. The firm develops products that help healthcare professionals in patient management and outcomes and assists clinicians with the detection of cardiovascular disease. It operates through the U.S. and International geographical segments. The U.S. segment produces and markets products, radiopharmacies, PMFs, integrated delivery networks, hospitals, clinics, and group practices throughout the United States. The International segment offers direct distribution in Canada and third-party distribution relationships in Europe, Canada, Australia, Asia-Pacific, Central America, and South America. The company was founded in 1956 and is headquartered in Bedford, MA.

LNTH
Lantheus Holdings Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest LNTH News

LNTH Lantheus Holdings Inc